JP2016535071A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535071A5 JP2016535071A5 JP2016543477A JP2016543477A JP2016535071A5 JP 2016535071 A5 JP2016535071 A5 JP 2016535071A5 JP 2016543477 A JP2016543477 A JP 2016543477A JP 2016543477 A JP2016543477 A JP 2016543477A JP 2016535071 A5 JP2016535071 A5 JP 2016535071A5
- Authority
- JP
- Japan
- Prior art keywords
- fxa variant
- variant protein
- composition
- acid sequence
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 100
- 102000004169 proteins and genes Human genes 0.000 claims 100
- 108010074860 Factor Xa Proteins 0.000 claims 65
- 239000000203 mixture Substances 0.000 claims 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims 33
- 150000001413 amino acids Chemical class 0.000 claims 32
- 239000012501 chromatography medium Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 7
- 150000004676 glycans Chemical class 0.000 claims 5
- 230000023597 hemostasis Effects 0.000 claims 5
- 238000012434 mixed-mode chromatography Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000005571 anion exchange chromatography Methods 0.000 claims 3
- 238000005277 cation exchange chromatography Methods 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 150000002402 hexoses Chemical class 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 238000001819 mass spectrum Methods 0.000 claims 2
- 239000002609 medium Substances 0.000 claims 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000009881 electrostatic interaction Effects 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 208000009429 hemophilia B Diseases 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 238000013060 ultrafiltration and diafiltration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361881834P | 2013-09-24 | 2013-09-24 | |
| US61/881,834 | 2013-09-24 | ||
| PCT/IB2014/064564 WO2015044836A1 (en) | 2013-09-24 | 2014-09-16 | Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535071A JP2016535071A (ja) | 2016-11-10 |
| JP2016535071A5 true JP2016535071A5 (OSRAM) | 2017-10-12 |
| JP6429885B2 JP6429885B2 (ja) | 2018-11-28 |
Family
ID=51844797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016543477A Expired - Fee Related JP6429885B2 (ja) | 2013-09-24 | 2014-09-16 | 組換えヒト凝固第ｘａ因子タンパク質の不均一集団を含む組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9757434B2 (OSRAM) |
| EP (1) | EP3049434A1 (OSRAM) |
| JP (1) | JP6429885B2 (OSRAM) |
| KR (1) | KR101988705B1 (OSRAM) |
| CN (2) | CN105579468A (OSRAM) |
| AR (1) | AR097732A1 (OSRAM) |
| AU (1) | AU2014326257B2 (OSRAM) |
| BR (1) | BR112016005899A8 (OSRAM) |
| CA (1) | CA2924981C (OSRAM) |
| HK (1) | HK1218760A1 (OSRAM) |
| IL (2) | IL244258A0 (OSRAM) |
| MX (1) | MX373466B (OSRAM) |
| MY (1) | MY173548A (OSRAM) |
| PE (1) | PE20160877A1 (OSRAM) |
| RU (1) | RU2648144C2 (OSRAM) |
| SA (1) | SA516370751B1 (OSRAM) |
| SG (1) | SG11201601221XA (OSRAM) |
| TW (1) | TWI631134B (OSRAM) |
| WO (1) | WO2015044836A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150343034A1 (en) | 2013-01-31 | 2015-12-03 | Pfizer Inc. | Compositions and methods for counteracting factor xa inhibition |
| CN105579468A (zh) | 2013-09-24 | 2016-05-11 | 辉瑞大药厂 | 包含重组人凝血因子Xa蛋白的异质性群体的组合物 |
| ES2875538T3 (es) | 2016-06-17 | 2021-11-10 | Alexion Pharma Inc | Preparación de derivados del factor Xa |
| EP3722418A1 (en) * | 2019-04-08 | 2020-10-14 | AB Enzymes Oy | Solution stable enzyme composition |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597799A (en) | 1990-09-04 | 1997-01-28 | Cor Therapeutics, Inc. | Recombinant agents affecting thrombosis |
| AT405517B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
| AT405516B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
| AT410216B (de) | 1999-08-10 | 2003-03-25 | Baxter Ag | Faktor x-analogon mit verbesserter aktivierbarkeit |
| AU2001249389A1 (en) | 2000-03-22 | 2001-10-03 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
| FR2831170B1 (fr) | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
| FR2841904B1 (fr) | 2002-07-03 | 2004-08-20 | Inst Nat Sante Rech Med | Analogues de facteurs x clivables par la thrombine |
| DK1781782T3 (da) | 2004-08-17 | 2010-08-23 | Csl Behring Gmbh | Modificerede vitamin K-afhængige polypeptider |
| EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| MX336958B (es) * | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| EP1820508A1 (en) | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| KR102069498B1 (ko) * | 2007-09-28 | 2020-01-23 | 포톨라 파마슈티컬스, 인코포레이티드 | 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법 |
| PL2300497T3 (pl) | 2008-06-24 | 2013-02-28 | Octapharma Ag | Sposób oczyszczania czynnika krzepnięcia VIII |
| US8455439B2 (en) | 2008-11-14 | 2013-06-04 | Portola Pharmaceuticals, Inc. | Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents |
| KR20110114587A (ko) | 2008-12-19 | 2011-10-19 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 세린 프로테아제 유도체 및 혈액응고 장애의 치료 또는 예방의 용도 |
| ES2605801T3 (es) | 2009-07-15 | 2017-03-16 | Portola Pharmaceuticals, Inc. | Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia |
| SI2591006T1 (sl) * | 2010-07-09 | 2019-10-30 | Bioverativ Therapeutics Inc | Enoverižne molekule, ki jih lahko obdelujemo in polipeptidi izdelani z njihovo uporabo |
| FR2972114B1 (fr) | 2011-03-01 | 2013-03-15 | Univ Grenoble 1 | Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur |
| EP2760887B1 (en) | 2011-09-30 | 2024-10-23 | The Children's Hospital of Philadelphia | Compositions and methods for modulating hemostasis |
| CN104755492A (zh) | 2012-07-25 | 2015-07-01 | 催化剂生物科学公司 | 修饰的因子x多肽及其应用 |
| US20150343034A1 (en) | 2013-01-31 | 2015-12-03 | Pfizer Inc. | Compositions and methods for counteracting factor xa inhibition |
| CN105579468A (zh) | 2013-09-24 | 2016-05-11 | 辉瑞大药厂 | 包含重组人凝血因子Xa蛋白的异质性群体的组合物 |
| WO2015066606A2 (en) | 2013-11-01 | 2015-05-07 | The Children's Hospital Of Philadelphia | Compositions and methods for increasing the half-life of factor xa |
| PT3096779T (pt) | 2014-01-24 | 2020-02-21 | Pfizer | Composições e métodos para tratamento de hemorragia intracerebral |
-
2014
- 2014-09-16 CN CN201480052212.2A patent/CN105579468A/zh active Pending
- 2014-09-16 CN CN202011112690.1A patent/CN112195169A/zh active Pending
- 2014-09-16 RU RU2016108608A patent/RU2648144C2/ru active
- 2014-09-16 AU AU2014326257A patent/AU2014326257B2/en not_active Ceased
- 2014-09-16 SG SG11201601221XA patent/SG11201601221XA/en unknown
- 2014-09-16 KR KR1020167007373A patent/KR101988705B1/ko not_active Expired - Fee Related
- 2014-09-16 CA CA2924981A patent/CA2924981C/en not_active Expired - Fee Related
- 2014-09-16 WO PCT/IB2014/064564 patent/WO2015044836A1/en not_active Ceased
- 2014-09-16 BR BR112016005899A patent/BR112016005899A8/pt not_active IP Right Cessation
- 2014-09-16 JP JP2016543477A patent/JP6429885B2/ja not_active Expired - Fee Related
- 2014-09-16 EP EP14792595.2A patent/EP3049434A1/en not_active Withdrawn
- 2014-09-16 HK HK16106674.2A patent/HK1218760A1/zh unknown
- 2014-09-16 MX MX2016003871A patent/MX373466B/es active IP Right Grant
- 2014-09-16 PE PE2016000398A patent/PE20160877A1/es unknown
- 2014-09-16 MY MYPI2016700985A patent/MY173548A/en unknown
- 2014-09-23 AR ARP140103512A patent/AR097732A1/es unknown
- 2014-09-23 TW TW103132803A patent/TWI631134B/zh not_active IP Right Cessation
- 2014-09-24 US US14/495,478 patent/US9757434B2/en not_active Expired - Fee Related
-
2016
- 2016-02-23 IL IL244258A patent/IL244258A0/en unknown
- 2016-03-17 SA SA516370751A patent/SA516370751B1/ar unknown
-
2017
- 2017-08-04 US US15/669,340 patent/US10660946B2/en active Active
-
2020
- 2020-05-25 US US16/882,598 patent/US20210106658A1/en not_active Abandoned
- 2020-12-13 IL IL279396A patent/IL279396A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2537862T3 (en) | A method of purifying coagulation factor VIII | |
| EP3040346B1 (en) | Process for the purification of granulocyte colony stimulating factor, g-csf | |
| RU2596408C2 (ru) | Способ очистки человеческого фактора, стимулирующего колонии гранулоцитов, из рекомбинантных е. coli | |
| FI4011908T3 (fi) | Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät | |
| FI3461261T3 (fi) | Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja | |
| PL409838A1 (pl) | Rekombinowane wirusy stowarzyszone z adenowirusem (AAV), kompozycje , wyizolowane białko kapsydu, wyizolowana lub syntetyczna cząsteczka kwasu nukleinowego, sposób wytwarzania rekombinowanych wirusów, komórki gospodarza, białka obejmujące fragment białka kapsydu AAV, sztuczne białka, rekombinowane wirusy, cząsteczki, sposoby dostarczania transgenu do komórki , sposób identyfikacji serotypu sekwencji wirusa (AAV), zestaw diagnostyczny, sposób izolacji nowych wirusów, nowe serotypy wirusa, wyizolowane wirusy, rekombinowana komórka, zastosowanie wirusa | |
| JP2016535071A5 (OSRAM) | ||
| CN101616930B (zh) | 疏水性蛋白质的纯化方法 | |
| Fortuna et al. | Use of sulfated cellulose membrane adsorbers for chromatographic purification of cell cultured-derived influenza A and B viruses | |
| EP3325614A1 (en) | Methods for purifying adenovirus vectors | |
| JP2014507368A5 (OSRAM) | ||
| US8536302B2 (en) | Dockerin polypeptide and method of purifying recombinant fused protein using the same | |
| CN101260145A (zh) | 一种重组人血清白蛋白及其融合蛋白的分离纯化工艺 | |
| Eckhardt et al. | Purification of oncolytic measles virus by cation-exchange chromatography using resin-based stationary phases | |
| CN104136121A (zh) | 减少离子交换色谱中的pH漂移 | |
| JP6232130B2 (ja) | ダルベポエチンアルファの精製方法 | |
| RU2016108608A (ru) | КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ГЕТЕРОГЕННЫЕ ПОПУЛЯЦИИ РЕКОМБИНАНТНЫХ БЕЛКОВ ЧЕЛОВЕЧЕСКОГО ФАКТОРА СВЕРТЫВАНИЯ КРОВИ Ха | |
| Chu et al. | High-throughput process development for recombinant human serum albumin separation from Pichia pastoris broth with mixed-mode chromatography | |
| CN105541994B (zh) | 一种血小板生成素或其变体或衍生物的纯化方法 | |
| CN110831956A (zh) | 重组蛋白 | |
| Schirmer et al. | Reduction of product‐related species during the fermentation and purification of a recombinant IL‐1 receptor antagonist at the laboratory and pilot scale | |
| Misterova et al. | Optimization of a Purification Method for the Recombinant Platelet-Derived Growth Factor rhPDGF-BB Expressed in the Methylotrophic Yeast Pichia Pastoris | |
| RU2528061C1 (ru) | Способ получения цитохрома с | |
| JP2001139600A (ja) | Ｉｌ−６ｒ・ｉｌ−６融合蛋白質の精製方法 | |
| JP2025520351A (ja) | ダウンストリーム抗体精製におけるｕｆ／ｄｆプールからの凝集体のクリアランス |